Extended data:
Ke Hua Biology: In July 2007, the company signed a long-term supply contract for AIDS diagnostic reagents (colloidal gold method) with the AIDS prevention and control project department of the Clinton Foundation of the United States, and the supply contract is valid for five years. The company's professional ability and product quality have been recognized for many times: "the overall scheme of AIDS testing and its series of products" won the title of national high-tech industrialization demonstration project; "HIV rapid diagnostic reagent research and industrialization project" won the third prize of Shanghai scientific and technological progress. In 2020, the company achieved a total revenue of 465,438+55 million, a year-on-year increase of 72.11%; Realized a gross profit of 2.422 billion, with a gross profit margin of 58.29%; The operating cash flow per share is 2.658 1 yuan.
Daan Gene: The company and its holding subsidiary * * * obtained the registration certificate of 16 medical devices issued by the US Food and Drug Administration, including blood screening HBV, HCV and HIV- 1 virus nucleic acid detection kit (PCR- fluorescent probe method). In 2020, the company achieved a total revenue of 5,345,438+billion, a year-on-year increase of 386.35%; Realized a gross profit of 3.779 billion, with a gross profit margin of 70.76%; The operating cash flow per share is 2.8667 yuan.
Anke biotechnology: 20 13, 12 In June, the processing status of the application for clinical trials of tenofovir disoproxil fumarate fumarate and tenofovir disoproxil fumarate fumarate tablets declared by Anhui Anke Hengyi Pharmaceutical Co., Ltd. was changed from "under approval" to "under approval-pending certification". Tenofovir disoproxil fumarate fumarate and tenofovir disoproxil fumarate fumarate tablets are nucleotide reverse transcriptase inhibitors, which are mainly used to treat AIDS, hepatitis B and other diseases in clinic. In 2020, the company achieved a total revenue of 65,438+07.05438+0 billion, a year-on-year increase of-0.65%; Realized a gross profit of 65,438+03.4 million, with a gross profit margin of 78.78%; Operating cash flow per share is 0.3404 yuan.
Zhangjiang Hi-Tech: Zhangjiang Hi-Tech: Shanghai Disno Biopharmaceutical Company, which is controlled by the company, has developed a new anti-AIDS imitation drug "deoxyinosine" and powder, and has obtained the new drug certificate and production approval. On September 1 day, 2003, Dicinno officially launched an anti-AIDS drug, Ketu, with zidovudine as its component, at a cost of only 5% to 7% of that of imported drugs, and has started mass production. In addition, desino has another anti-AIDS drug-nevirapine, which has entered the acceptance stage in the State Administration of Pharmaceutical Products and is also the most basic anti-AIDS drug. The company achieved a total revenue of 779 million in 2020, a year-on-year increase of-47.23%; The gross profit was 429.4 million, and the gross profit margin was 55.11%; The operating cash flow per share is 0. 1063 yuan.